Inflammation as potential target for therapy to target residual risk post ACS - PACE-CME

Inflammation as potential target for therapy to target residual risk post ACS

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Extra work of checking device data weekly does not translate into benefit for HF patient
Extra work of checking device data weekly does not translate into benefit for HF patient
ESC 2016
Extra work of checking device data weekly does not translate into benefit for HF patient
- Martin Cowie, MD
Heart Failure news from ESC 2016 at a glance
Heart Failure news from ESC 2016 at a glance
ESC 2016
Heart Failure news from ESC 2016 at a glance
- Prof. Mariell Jessup
Mendelian randomisation study suggests that CV prevention could be simpler and more effective
Mendelian randomisation study suggests that CV prevention could be simpler and more effective
ESC 2016
Mendelian randomisation study suggests that CV prevention could be simpler and more effective
- Dr. Brian Ference
Iron deficiency in the new HF guidelines
Iron deficiency in the new HF guidelines
ESC 2016
Iron deficiency in the new HF guidelines
- Peter van der Meer, MD